GLPwatch
Xultophy for Bipolar disorder
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCXultophy (liraglutide) is not FDA-approved for bipolar disorder, and any use for this condition is off-label or investigational. Research includes animal studies suggesting potential effects on mania-like behaviors and memory deficits, as well as clinical observations of psychiatric adverse events.
AI summary of the sources below.
| Drug | Xultophy (liraglutide) |
|---|---|
| Condition | Bipolar disorder |
| Approval status | Investigational / off-label |
| Research papers | 10 |
Xultophy is not FDA-approved for bipolar disorder; the research below reflects investigational or off-label study only.
Research on liraglutide for bipolar disorder (10)
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
- The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder.
- Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder.
- Liraglutide for psychiatric disorders: clinical evidence and challenges.
- Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.
- Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study.
- GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state <i>via</i> GSK-3β pathway.
- Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.
- Liraglutide attenuates clozapine-induced mitochondrial dysfunction and improves energy metabolism in the brain of rats.
- Patient experiences with liraglutide for obesity and binge eating disorder-A qualitative study.